Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial
Tóm tắt
COVID-19 is a significant global threat to public health. Despite the availability of vaccines and anti-viral drugs, there is an urgent need for alternative treatments to help prevent and/or manage COVID-19 symptoms and the underlying dysregulated immune response. We hypothesized that administration of Inflawell® syrup, a Boswellia extract formulation enriched for boswellic acids (BAs), can reduce the excessive or persistent inflammation and thereby prevent disease progression. BAs are medicinally activated triterpenoids found in the resins of Boswellia spp., and possess an immense therapeutic potential due to their anti-inflammatory and immunoregulatory activities. We investigated the effect of Inflawell® syrup, on moderate COVID-19 patients along with the current standard of care treatment. A randomized placebo-controlled double-blind clinical trial was conducted, following definitive confirmation of COVID-19. Forty-seven hospitalized patients with moderate COVID-19 were enrolled and received either the Inflawell® syrup or placebo. Clinical symptoms and markers of inflammation were evaluated at baseline and completion of the trial. Our clinical trial revealed an increase in the percentage of oxygen saturation level in patients that received the BAs compared to placebo (P < 0.0001). In addition, the average duration of hospitalization was significantly shorter in the BAs group compared with the placebo group (P < 0.04). Concomitantly, some improvement in the clinical symptoms including cough, dyspnea, myalgia, headache, and olfactory and gustatory dysfunction were detected in the BAs group. Hematologic findings showed a significant decrease in the percentage of neutrophils (P < 0.006) and neutrophil-to-lymphocyte ratio (NLR) levels (P < 0.003), associated with a significant increase in the percentage of lymphocytes in the BAs group compared with the placebo (P < 0.002). Additionally, a significant decrease in CRP, LDH, IL − 6 and TNF − α levels was detected in the BAs group. Following the intervention, fewer patients in the BAs group were PCR-positive for COVID-19 compared to placebo, though not statistically significant. Overall, the treatment with Inflawell® resulted in shorter hospital stay, alleviation of COVID-19 clinical symptoms and decline in the level of pro-inflammatory cytokines. The trial has been registered in
https://www.irct.ir
with unique identifier: IRCT20170315033086N10 (
https://en.irct.ir/trial/51631
). IRCT is a primary registry in the WHO registry network (
https://www.who.int/clinical-trials-registry-platform/network/primary-registries
).
Tài liệu tham khảo
Alkhatip AAAMM, Kamel MG, Hamza MK, Farag EM, Yassin HM, Elayashy M, Naguib AA, Wagih M, Abd-Elhay FA-E, Algameel HZ, Yousef MA, Purcell A, Helmy M (2021) The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis. Expert Rev Mol Diagn 21(5):505–514. https://doi.org/10.1080/14737159.2021.1915773
Baram SM, Karima S et al (2019) Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: a randomized, double-blind, placebo-controlled, pilot trial. Inflammopharmacology 27(6):1101–1112. https://doi.org/10.1007/s10787-019-00627-z
Boechat JL, Chora I, Morais A, Delgado L (2021) The immune response to SARS-CoV-2 and COVID-19 immunopathology - current perspectives. Pulmonology 27(5):423–437. https://doi.org/10.1016/j.pulmoe.2021.03.008
Cai J, Li H, Zhang C, Chen Z, Liu H, Lei F, Qin J-J, Liu Y-M, Zhou F, Song X, Zhou J, Zhao Y-C, Wu B, He M, Yang H, Zhu L, Zhang P, Ji Y-X, Zhao G-N, Lu Z, Liu L, Mao W, Liao X, Lu H, Wang D, Xia X, Huang X, Wei X, Xia J, Zhang B-H, Yuan Y, She Z-G, Xu Q, Ma X, Wang Y, Yang J, Zhang X, Zhang X-J, Li H (2021) The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19. Cell Metab 33(2):258-269.e253. https://doi.org/10.1016/j.cmet.2021.01.002
Caliebe RH, Scior T, Ammon HPT (2021) Binding of boswellic acids to functional proteins of the SARS-CoV-2 virus: bioinformatic studies. Arch Pharm 354(11):2100160
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C (2020) Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther 5(1):84. https://doi.org/10.1038/s41392-020-0191-1
Cazzolla AP, Lovero R, Lo Muzio L, Testa NF, Schirinzi A, Palmieri G, Pozzessere P, Procacci V, Di Comite M, Ciavarella D, Pepe M, De Ruvo C, Crincoli V, Di Serio F, Santacroce L (2020) Taste and smell disorders in COVID-19 patients: role of interleukin-6. ACS Chem Neurosci 11(17):2774–2781. https://doi.org/10.1021/acschemneuro.0c00447
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001
D’Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A (2021) Randomized clinical trial olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs intervention treatment with Palmitoylethanolamide and Luteolin: preliminary results. Eur Rev Med Pharmacol Sci 25(11):4156–4162
Dogan A, Mustafa G, Dervis T, Orhan A (2021) Diagnostic and early prognostic value of serum CRP and LDH levels in patients with possible COVID-19 at the first admission. J Infect Dev Countries. https://doi.org/10.3855/jidc.14072
Du Z, Liu Z, Ning Z, Liu Y, Song Z, Wang C, Lu A (2015) Prospects of boswellic acids as potential pharmaceutics. Planta Med 81(4):259–271. https://doi.org/10.1055/s-0034-1396313
Dudine L, Canaletti C, Giudici F, Lunardelli A, Abram G, Santini I, Baroni V, Paris M, Pesavento V, Manganotti P, Ronchese F, Gregoretti B, Negro C (2021) Investigation on the loss of taste and smell and consequent psychological effects: a cross-sectional study on healthcare workers who contracted the COVID-19 infection. Front Public Health 9:511
Ghizlane EA, Manal M, Abderrahim EK, Abdelilah E, Mohammed M, Rajae A, Amine BM, Houssam B, Naima A, Brahim H (2021) Lymphopenia in Covid-19: a single center retrospective study of 589 cases. Ann Med Surg 69:102816. https://doi.org/10.1016/j.amsu.2021.102816
Gomaa AA, Mohamed HS, Abd-Ellatief RB, Gomaa MA (2021) Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly. Inflammopharmacology. https://doi.org/10.1007/s10787-021-00841-8
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A (2020) Baseline characteristics and outcomes of 1591 patients infected With SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323(16):1574–1581. https://doi.org/10.1001/jama.2020.5394
Hazeldine J, Lord JM (2021) Neutrophils and COVID-19: active participants and rational therapeutic targets. Front Immunol 12:680134–680134. https://doi.org/10.3389/fimmu.2021.680134
Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, Lippi G (2020) Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med 38(9):1722–1726. https://doi.org/10.1016/j.ajem.2020.05.073
Ho P, Zheng J-Q, Wu C-C, Hou Y-C, Liu W-C, Lu C-L, Zheng C-M, Lu K-C, Chao Y-C (2021) Perspective adjunctive therapies for COVID-19: beyond antiviral therapy. Int J Med Sci 18(2):314–324. https://doi.org/10.7150/ijms.51935
Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild M, Kann G, Wolf T, Gottschalk R, Ciesek S (2020) Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med 382(13):1278–1280. https://doi.org/10.1056/NEJMc2001899
Kadhim MM, Washeel Salman A, Mrebee Zarzoor A, Kadhum WR (2021) Inhibition of SARS-CoV-2 reproduction using Boswellia carterii: a theoretical study. J Mol Liq 337:116440. https://doi.org/10.1016/j.molliq.2021.116440
Kong M, Zhang H, Cao X, Mao X, Lu Z (2020) Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect 148:e139–e139. https://doi.org/10.1017/S0950268820001557
Kooper DCH, Mkadmi H (2021) Self-reported olfactory and gustatory dysfunction in patients with COVID-19 infection*. Rhinology Online 4:140–146
Laurendon T, Radulesco T, Mugnier J, Gérault M, Chagnaud C, El Ahmadi AA, Varoquaux A (2020) Bilateral transient olfactory bulb edema during COVID-19-related anosmia. Neurology 95(5):224–225. https://doi.org/10.1212/wnl.0000000000009850
Li S, Cheng C-S, Zhang C, Tang G-Y, Tan H-Y, Chen H-Y, Wang N, Lai AY-K, Feng Y (2021) Edible and herbal plants for the prevention and management of COVID-19. Front Pharmacol 12:900
Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, Luo M, Chen L, Zhao Y (2020) Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 81(1):e6–e12. https://doi.org/10.1016/j.jinf.2020.04.002
Mahat RK, Panda S, Rathore V, Swain S, Yadav L, Sah SP (2021) The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Epidemiol Glob Health 11:100727–100727. https://doi.org/10.1016/j.cegh.2021.100727
Matthay MA, Luetkemeyer AF (2021) IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how? JAMA 326(6):483–485. https://doi.org/10.1001/jama.2021.11121
Olbei M, Hautefort I, Modos D, Treveil A, Poletti M, Gul L, Shannon-Lowe CD, Korcsmaros T (2021) SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely Ill patients. Front Immunol 12:381
Padmanaban KG, Radheshyam N (2021) Role of herbal immunomodulator (Viranorm) as add-on treatment in asymptomatic or mildly symptomatic COVID-19 confirmed cases. Indian J Clin Pract 32(3):187–193
Peng X, Ouyang J, Isnard S, Lin J, Fombuena B, Zhu B, Routy J-P (2020) Sharing CD4+ T cell loss: when COVID-19 and HIV collide on immune system. Front Immunol 11:596631–596631. https://doi.org/10.3389/fimmu.2020.596631
Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, Nuccetelli M, Vadacca GB, Guidetti D, Vercelli A, Magnacavallo A, Bernardini S, Terracciano C (2020) Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta 509:135–138. https://doi.org/10.1016/j.cca.2020.06.012
Pum A, Ennemoser M, Adage T, Kungl AJ (2021) Cytokines and chemokines in SARS-CoV-2 infections-therapeutic strategies targeting cytokine storm. Biomolecules 11(1):91. https://doi.org/10.3390/biom11010091
Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Baßler K, Schultze JL, Aschenbrenner AC (2021) Neutrophils in COVID-19. Front Immunol 12:952
Roy NK, Parama D, Banik K, Bordoloi D, Devi AK, Thakur KK, Padmavathi G, Shakibaei M, Fan L, Sethi G, Kunnumakkara AB (2019) An update on pharmacological potential of boswellic acids against chronic diseases. Int J Mol Sci 20(17):4101. https://doi.org/10.3390/ijms20174101
Singh NA, Kumar P, Jyoti KN (2021) Spices and herbs: Potential antiviral preventives and immunity boosters during COVID-19. Phytother Res. https://doi.org/10.1002/ptr.7019.10.1002/ptr.7019
Sproston NR, Ashworth JJ (2018) Role of C-Reactive protein at sites of inflammation and infection. Front Immunol 9:754–754. https://doi.org/10.3389/fimmu.2018.00754
Suresh K (2011) An overview of randomization techniques: an unbiased assessment of outcome in clinical research. J Hum Reprod Sci 4(1):8–11. https://doi.org/10.4103/0974-1208.82352
Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L (2020) Clinical outcomes in 55 patients with severe acute respiratory syndrome Coronavirus 2 who were asymptomatic at hospital admission in Shenzhen, China. J Infect Dis 221(11):1770–1774. https://doi.org/10.1093/infdis/jiaa119
Wang J-T, Sheng W-H, Fang C-T, Chen Y-C, Wang J-L, Yu C-J, Chang S-C, Yang P-C (2004) Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 10(5):818–824. https://doi.org/10.3201/eid1005.030640
Yang S-C, Tsai Y-F, Pan Y-L, Hwang T-L (2021) Understanding the role of neutrophils in acute respiratory distress syndrome. Biomed J 44(4):439–446. https://doi.org/10.1016/j.bj.2020.09.001
Zeng Z-Y, Feng S-D, Chen G-P, Wu J-N (2021) Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: a prospective cohort study. BMC Infect Dis 21(1):80. https://doi.org/10.1186/s12879-021-05796-3
Zhou S, Feng J, Xie Q, Huang T, Xu X, Zhou D, Zhang W, Sun S, Liu X, Wu X, Che J, Fan T, Zou D, Wang J, Zhan D, Peng D, Feng Y, Yu G, Yuan Z, Fang B (2021) Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: a randomized controlled multicenter trial. Phytomedicine 89:153612–153612. https://doi.org/10.1016/j.phymed.2021.153612
Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS (2020) Neutrophil extracellular traps in COVID-19. JCI Insight. https://doi.org/10.1172/jci.insight.138999